AzTrials
AzTrials

Systemic Sclerosis (SSc)DERMATOMICSNCT06894654

DERMATOMICS: Identifying Regulators of Skin Homeostasis

An observational study of Systemic Sclerosis (SSc), run by Relation Therapeutics at 2 sites in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Diseases of the skin associated with chronic immune driven conditions, including scleroderma, lupus, dermatomyositis, psoriasis, and atopic dermatitis, significantly impact skin integrity, function, and overall quality of life. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Systemic Sclerosis (SSc)
What is being tested?
Skin punch biopsy, blood sampling and Questionnaire
How many people
500 participants
Where
2 sitesUnited Kingdom
Study dates
10 Dec 2024to 1 Nov 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Participants with either early systemic sclerosis (SSc) or late systemic sclerosis (SSc)

Who may be able to join

  • SSc participant cohort:
  • Age of 18 years inclusive, or older at the time of signing the informed consent
  • Documented diagnosis of systemic scleroderma (SSc) (early or late diagnosis)
  • Healthy cohort:
  • Approximate age/sex matching (majority of healthy participants to be recruited after cohort 1 and 2)
  • Absence of Raynaud's Phenomenon
  • Absence of lung disease
  • Not on immunosuppressive treatment

Who cannot join

  • SSc participant cohort:
  • Participants unable to provide informed consent.
  • Participants with suspected/established underlying malignancy.
  • Participants with suspected/established skin cancer.
  • Participants with suspected/established bloodborne disease.
  • Current enrolment or past participation in a study involving an investigational drug within 3 months or 5 half-lives of the investigational drug treatment (whichever is longer) before the day of sample collection.
Show all 13Show fewer
  • Participants treated with cellular therapies, e.g., HSCT, Car-T cells, T cell engagers.
  • Participants treated with B-cell depletion therapies within 6 months.
  • Concurrent diagnosis of any other connective tissue disease (CTD) in overlap.
  • Diagnosis of other non-SSc dermatological conditions.
  • Systemic sclerosis-like illness, including but not limited to localised scleroderma (morphoea), eosinophilic fasciitis, sclerodermoid graft-versus-host disease, fibro mucinous conditions (scleredema, scleromyxedema), scleroderma-like conditions that are associated with environmental chemical and drug exposure (e.g., toxic rapeseed oil, vinyl chloride, bleomycin, gadolinium-based contrast agents [nephrogenic systemic fibrosis], or due to metabolic disease).
  • History or presence of significant non-sclereoderma related cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurological disorders, or treatments for those, capable of significantly interfering with the results and interpretation of data.
  • Smoking history (5 years smoke free acceptable)

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom2 sites, 2 recruiting
  • Chapel Allerton Hospital

    Leeds, LS7 4SA

    Sumit Lahiri, 01133924879, sumit.lahiri@nhs.net

    Not yet recruiting
  • Royal Free Hospital

    London, NW3 2QG

    Kimberley Morlese, 0207 317 7544 ext. 34274, kimberley.morlese@nhs.net

    Recruiting

Other trials in United Kingdom

About this study

Diseases of the skin associated with chronic immune driven conditions, including scleroderma, lupus, dermatomyositis, psoriasis, and atopic dermatitis, significantly impact skin integrity, function, and overall quality of life. These conditions can lead to severe disfigurement, discomfort, and systemic complications, necessitating long-term medical intervention. The prevalence of these skin disorders is rising globally, driven by genetic, environmental, and immunological factors. Unravelling the mechanisms leading to skin manifestations may shed further insights in the overall mechanisms of disease.

The DERMATOMICS study will focus on understanding systemic sclerosis (SSc) biology.

Read more

Systemic Sclerosis (SSc) is a highly heterogeneous rare autoimmune fibrotic condition affecting the skin and internal organs. SSc is classified as a Connective Tissue Disease (CTD), a family of conditions including Systemic Lupus Erythematosus, Sjogren Syndrome and Inflammatory Myositis, all characterised by an autoimmune process affecting the connective tissue of most organs, communed by the presence of anti-nuclear antibodies (ANA). In SSc, patients are affected by a combination of tissue and vascular fibrosis, on the background of a chronic inflammatory process, leading to the highest per patient morbidity and mortality across CTDs. The main driver of mortality to date is interstitial lung disease (ILD), which is the consequence of the fibrotic involvement of the lungs, leading to a progressive loss of functional lung volumes, and ultimately, derangement of lung circulation, hypoxia, increased risk of hospitalisation for lower respiratory infections and death.

Current treatments for CTDs include general immunosuppressive treatments, not necessarily targeted to the specific mechanisms underlying their presentation, focusing on reducing inflammation and managing symptoms rather than addressing the underlying causes. Many of these therapies have limited effectiveness or are burdened with significant side effects. Therefore, there is a critical need to develop a comprehensive understanding of the cellular and molecular mechanisms underlying these disorders to identify novel therapeutic targets.

Several factors contribute to the risk and severity of SSc, including genetic predisposition, environmental triggers, immune system dysregulation, and lifestyle factors such as diet and smoking. The interactions between these factors are complex and not fully understood. By recruiting participants with SSc, we aim to obtain skin punch biopsies for detailed molecular and genetic analysis. To increase the informative value of our study we plan to implement an extreme phenotype approach and include participants with opposite degrees of severity.

Our study aims to elucidate the relationships between the molecular biology of skin cells, skin structure, genetic factors ("DNA"), and environmental influences. The goal is to identify and validate novel therapeutic targets that can lead to more effective and personalised treatment options for SSc, and more broadly for CTDs and CTD-associated skin and lung disease.

Modern single-cell technologies will be employed to dissect the cellular diversity within the skin. These advanced techniques have revolutionised our understanding of many tissues, but skin tissues remain underexplored, especially in the context of chronic skin diseases. Protocols for skin punch biopsy and single-cell profiling are well-established, allowing us to systematically analyse how genetic variations influence skin structure and function.

Being tested
Skin punch biopsy, blood sampling, Questionnaire
Keywords
Scleroderma, Skin, systemic sclerosis, SSc
Medical subject headings
Scleroderma, Systemic, Scleroderma, Diffuse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Skin punch biopsyProcedure or surgery

    Skin punch biopsies are 5mm for this study. Participants with SSc will undergo 4 biopsies (2 in diseased area, 2 in non-diseased area if available). Healthy Volunteers will undergo 2 biopsies.

  • blood samplingOther

    10mls blood will be taken for analysis and DNA sequencing

  • QuestionnaireBehavioural

    All participants are required to complete a questionnaire with information on demographics, lifestyle, medical and medication history.

Study groups in NCT06894654
Study groupRoleWhat they receive
Early SSc cohortEarly diagnosis of systemic sclerosis (SSc)
Receives: Procedure: Skin punch biopsy; Other: blood sampling; Behavioral: Questionnaire
Late SSc cohortLate diagnosis of systemic sclerosis (SSc)
Receives: Procedure: Skin punch biopsy; Other: blood sampling; Behavioral: Questionnaire
Healthy cohort (control)Absence of SSc and Raynaud's Phenomenon (controls for the SSc cohorts)
Receives: Procedure: Skin punch biopsy; Other: blood sampling; Behavioral: Questionnaire

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acquisition of skin samples

    Skin samples acquired from skin punch biopsies to be used for the study of RNA.

    Measured: Within 48 hours of sampling

Secondary outcomes (2)
  1. Acquisition of 10ml of blood

    Blood to use used for genetic sequencing, and/or other downstream omics/assays

    Measured: Within 48 hours of sampling

  2. Completion of participant questionnaire

    Participant metadata to be used to understand cohort and identify confounding factors

    Measured: EDC entry within 1 week of skin & blood samples being taken.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Mar 2025
  2. Study start10 Dec 2024
  3. Primary completion1 Nov 2027 (estimated)
  4. Study completion1 Nov 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06894654
Sponsor's protocol ID
RRx-Profiling-002
Acronym
DERMATOMICS
Status last verified
Aug 2026
First submitted
18 Mar 2025
Last updated
14 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: A pharmaceutical partner is providing funding support to a research collaboration with Relation Therapeutics and will be involved in data review. It is intended that the results of the study will be published when appropriate. There will be no reference in the study results / reports / publications to any information that would identify participants. The final dataset, which may include a small number of select fields from the EDC database, will not contain any identifiable personal data.

Questions about this trial

What is this clinical trial studying?

An observational study of Systemic Sclerosis (SSc), run by Relation Therapeutics at 2 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acquisition of skin samples (time frame: Within 48 hours of sampling). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in